drugset / Trial / NCT04524208
A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3
NaSingle-groupOpen-labelTreatment
Summary
The main objective of this clinical trial represents the evaluation of efficacy of the tyrosine kinase inhibitor Cabozantinib in patients with NEN G3 with a proliferation rate of Ki67 20 - 60%.
Timeline
- Start
- 2021-03-01
- Primary completion
- 2024-09-30
- Completion
- 2024-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabozantinib | Small molecule | 60 mg | Oral |